Back

GLP-1 receptor agonists: from glycaemic control to cardio-reno-metabolic disease modification

European Heart Journal - Quality of Care and Clinical Outcomes

4 June 2026
Organised by: Logo
Read full article
ESC Journals CARDIOVASCULAR PHARMACOLOGY HEART FAILURE Chronic Heart Failure PREVENTIVE CARDIOLOGY Risk Factors and Prevention

Contributors

Dimitrios Farmakis
Dimitrios Farmakis

Author

National & Kapodistrian University of Athens Athens , Greece

Konstantinos I Karampinos
Konstantinos I Karampinos

Author

Attikon University Hospital Athens , Greece

Gerasimos Filippatos
Gerasimos Filippatos

Author

National & Kapodistrian University of Athens Medical School Athens , Greece

You may be interested in
thumbnail
Webinar
GLP-1 RAs and HFpEF : what do we know from large RCTs about GLP-1 RAs and their effects on HFpEF?
24 November 2025
thumbnail
Congress Presentation
Sodium-glucose cotransporter-2 inhibitors and their combination with glucagon like peptide-1 receptor agonists improve endothelial glycocalyx and arterial stiffness in type-2 diabetes
28 August 2020
thumbnail
Congress Presentation
GLP-1 receptor and cardiovascular outcomes among patients with diabetes on dialysis:– insights from the TriNetX real-world database
31 August 2026
thumbnail
Congress Presentation
Is GLP-1 insufficiency a coronary risk factor? - a multicenter observational study, BOREAS-CAD2
27 August 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources